Arvinas secures $350 million in private placement for drug development By Investing.com – Canada Boosts
© Reuters. Arvinas, Inc., a biopharmaceutical firm specializing in protein degradation-based therapies, has introduced the profitable association of a personal placement deal which is anticipated to generate roughly $350 million. The deal entails the sale of round 12.96 million widespread inventory shares at $21.36 every, alongside pre-funded warrants for a further 3.42 million shares at…
